Sequent Scientific has announced a merger with Viyash Life Sciences to form a platform with strong leadership in animal pharmaceuticals. This new combined entity aims to have integrated capabilities across the global pharmaceutical market, enhancing its operational strength and research and development foundation.
The board of directors at Sequent Scientific approved a scheme of amalgamation for the merger of Viyash Life Sciences, along with its group companies, into Sequent Research Limited, a wholly-owned subsidiary of Sequent Scientific. This merger falls under the applicable provisions of the Companies Act, 2013.
Sequent Scientific, a listed company with operating profits of around ₹100 crore in FY 2023-24, is joining forces with Viyash Life Sciences, which reported operating profits of around ₹150 crore in the same period.
Sequent’s CEO, Rajaram Narayanan, expressed enthusiasm about the merger, highlighting its potential to strengthen Sequent’s global presence in animal health and expand its R&D capabilities.
Each shareholder of Viyash Life Sciences will receive 56 equity shares of Sequent Scientific for every 100 shares held. This share swap will result in the expansion of Sequent Scientific’s capital base from approximately 24.95 crore shares to 42.89 crore shares. The combined entity will have a promoter shareholding of around 62.4%.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
